SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease

Gastrointestinal Endoscopy

Volumn 81, Issue 3, 2015, Pages 489-501.e26

  Laine, Loren ^a,b   Kaltenbach, Tonya ^c   Barkun, Alan ^d   McQuaid, Kenneth R ^e   Subramanian, Venkataraman ^f   Soetikno, Roy ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOENDOSCOPY; COLON MUCOSA; COLONOSCOPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DISEASE SURVEILLANCE; DYSPLASIA; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; NARROW BAND IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT PLANNING; VIDEOENDOSCOPY; WHITE LIGHT ENDOSCOPY; COLON RESECTION; COLORECTAL NEOPLASMS; COMPLICATION; HEALTH SURVEY; PATHOLOGY; PROCEDURES;

COLECTOMY; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; NARROW BAND IMAGING; POPULATION SURVEILLANCE;

EID: 84923272182     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2014.12.009     Document Type: Conference Paper

References (74)

1. Farraye FA, Odze RD, Eaden J, et al. AGA Medical Position Statement on the Diagnosis and Management of Neoplasia in Inflammatory Bowel Disease. Gastroenterology 2010;138:738-45.
2. Farraye FA, Odze RD, Eaden J, et al. AGA Technical Review on the diagnosis and management of colorectal dysplasia in inflammatory bowel disease. Gastroenterology 2010;138:746-74.
3. Leighton JA, Shen B, Baron TH, et al. ASGE Guidelines: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006;63:558-65.
4. Itzkowitz SH, Present DH; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-21.
5. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4.
6. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004;6: 334-9.
7. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 2007;65:998-1004.
8. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1-33.
9. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
10. Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical Practice Guidelines for Surveillance Colonoscopydin adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease. Sydney: Cancer Council Australia; 2011.
11. Graham R, Mancher M, Wolman DM, et al. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academy of Sciences, 2011.
12. Woolf SH, Schunemann HJ, Eccles MP, et al. Developing Clinical Practice Guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. Implementation Sci 2012;7:1-12.
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
14. Schunemann HJ, Wiercioch W, Etxeandia I, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ 2014;186:E123-42.
15. The Paris classification of superficial neoplastic lesions: esophagus, stomach, and colon. Gastrointest Endosc 2003;58(suppl):S3-43.
16. Subramanian V, Ragunath K. Advanced endoscopic imaging: a review of commercially available technologies. Clin Gastroenterol Hepatol 2014;12:368-76.
17. Subramanian V, Ramappa V, Telakis E, et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. Inflamm Bowel Dis 2013;19:350-5.
18. Soetikno R, Subramanian V, Kaltenbach T, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology 2013;144: 1349-52.e6.
19. Kaltenbach T, Sano Y, Friedland S, et al. American Gastroenterological Association (AGA) Institute Technology Assessment on Image Enhanced Endoscopy. Gastroenterology 2008;134:327-40.
20. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880-8.
21. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007;132:874-82.
22. Chiorean MV, Helper DJ, Saxena R, et al. Targeted biopsies using chromoendoscopy can replace random biopsies in patients with IBD at high risk for colorectal neoplasia. Gastroenterology 2012;142(suppl 1): S339.
23. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256-60.
24. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008;103:2342-9.
25. Matsumoto T, Nakamura S, Jo Y, et al. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol 2003;98:1827-33.
26. Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 2011;23:680-9.
27. Gunther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: Comparison of random biopsy vs. targeted biopsy protocols International. J Colorectal Dis 2011;26:667-72.
28. Konijeti GG, Shrime MG, Ananthakrishnan A, et al. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. Epub 2013 Nov 18.
29. Wang YR, Cangemi JR, Loftus EV Jr, et al. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol 2013;108:444-9.
30. Picco MF, Pasha S, Leighton JA, et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis 2013;19:1913-20.
31. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007;39:216-21.
32. Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Amer J Gastroenterol 2012;107:885-90.
33. van den Broek FJC, Fockens P, Van ES, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy 2011;43:108-15.
34. Bisschops R, Bessissow T, Baert FJ, et al. Chromo-endoscopy versus narrow band imaging in ulcerative colitis: a prospective randomized controlled trial [abstract]. Gastrointest Endosc 2012;75(suppl 1): AB148.
35. Feitosa F, Carlos A, Guilherme NJ, et al. Narrow-band imaging and chromoendoscopy for the detection of colonic dysplasia in inflammatory bowel disease: a prospective and randomized study. Inflamm Bowel Dis 2011;17:S14-5.
36. Efthymiou M, Allen PB, Taylor ACF, et al. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2132-8.
37. Pellise M, Lopez-Ceron M, Rodriguez de Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc 2011;74: 840-8.
38. Moussata D, Allez M, Cazals-Hatem M, et al. Are random biopsies still useful for the detection of intraepithelial neoplasia in IBD patients undergoing surveillance colonoscopy with chromoendoscopy? Gut 2012;61(suppl 3):A24.
39. van den Broek FJC, Fockens P, Van ES, et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 2008;57:1083-9.
40. Jaramillo E, Watanabe M, Befritis R, et al. Small, flat colorectal neoplasias in long-standing ulcerative colitis detected by highresolution electronic video endoscopy. Gastrointest Endosc 1996;44:15-22.
41. Blonksi W, Kundu R, Lewis J, et al. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastronterol 2008;43:698-703.
42. Naymagon S, Marion JF. Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement. Gastrointest Endosc Clin N Am 2013;23:679-94.
43. Voorham QJ, Rondagh EJ, Knol DL, et al. Tracking the molecular features of nonpolypoid colorectal neoplasms: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:1042-56.
44. Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2:534-41.
45. Goldstone R, Itzkowitz S, Harpaz N, et al. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest Endosc 2011;74:1087-93.
46. Van Shaik F, Mooiweer E, van der Have M, et al. Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia. Inflamm Bowel Dis 2013;19:342-9.
47. Kisiel JB, Loftus EV Jr, Harmsen WS, et al. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis 2012;18: 226-35.
48. Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Progression of lowgrade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohn's Colitis 2013;7: e684-91.
49. Blonksi W, Kundu R, Furth DF, et al. High-grade dysplastic adenomalike mass lesions are not an indication for colectomy in patients with ulcerative colitis. Scand J Gastronterol 2008;43:817-20.
50. Wanders LK, Dekker E, Pullens B, et al. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2014;12: 756-64.
51. Siegel CA, Schwartz LM, Woloshin S, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis 2010;16:1658-62.
52. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844-57.
53. Ullman TA, Loftus EV Jr, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002;97:922-7.
54. Ullman TA, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311-9.
55. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007;25:657-68.
56. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-8.
57. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.
58. Hata K, Watanabe T, Kazama S, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer 2003;89:1232-6.
59. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 2008;6:993-8.
60. Odze RD, Goldblum J, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002;15:379-86.
61. Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001;194:152-7.
62. Dixon MF, Brown LJR, Gilmour HM, et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988;13: 385-97.
63. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
64. Soetikno R, Sanduleanu S, Kaltenbach T. An atlas of the nonpolypoid colorectal neoplasms in inflammatory bowel disease. Gastrointest Endosc Clin N Am 2014;24:483-520.
65. Matsumoto T, Iwao Y, Igarashi M, et al. Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. Inflamm Bowel Dis 2008;14:259-64.
66. Ueno Y, Tanaka S, Chayama K. Non-polypoid colorectal neoplasms in ulcerative colitis. Gastrointest Endosc Clin N Am 2010;20:525-42.
67. Kaltenbach T, McQuaid K, Sanchez-Yague A, et al. Chromoendoscopy with targeted biopsy to detect nonpolypoid colorectal neoplasms in inflammatory bowel disease. ASGE Educational Products and CME Program Audiovisual Award, 2014. Available at: http://www.youtube.com/ watch?vZOARkbgwlObI. Accessed January 7, 2015.
68. Soetikno RM, Gotoda T, Nakanishi Y, et al. Endoscopic mucosal resection. Gastrointest Endosc 2003;57:567-79.
69. Soetikno R, Kaltenbach T. Dynamic submucosal injection technique. Gastrointest Endosc Clin N Am 2010;20:497-502.
70. East JE, Toyonaga T, Suzuki N. Endoscopic management of nonpolypoid colorectal lesions in colonic IBD. Gastrointest Endosc Clin N Am 2014;24:435-45.
71. Rutter M, Bernstein C, Matsumoto T, et al. Endoscopic appearance of dysplasia in ulcerative colitis and the role of staining. Endoscopy 2004;36:1109-14.
72. Nett A, Velayos F, McQuaid K. Quality bowel preparation for surveillance colonoscopy in patients with inflammatory bowel disease is a must. Gastrointest Endosc Clin N Am 2014;24:379-92.
73. Kozarek R, Chiorean MV, Wallace M. Endoscopy in inflammatory bowel disease. Switzerland: Springer; 2015.
74. Kaltenbach T, Soetikno R. Nonpolypoid colorectal neoplasms in inflammatory bowel disease. Philadelphia: Elsevier; 2014.